Ozempic, Wegovy and Mounjaro can still be expensive, but pharmacy produced GLP-1 compounds are becoming much more affordable.

Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...

A new generation of GLP-1 drugs promising fast results continues to rock the weight loss industry, which has emphasized ...

It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...

Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.

Novo Nordisk now expects sales to grow 13% to 21% in constant currencies this year, from 16% to 24% previously. Operating profit should grow 16% to 24% compared with a previous target of 19% to 27%.

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

The Ohio Board of Pharmacy recently revoked the licenses of four Ohio medical spas, with concerns over the sourcing and ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Wegovy, the popular weight-loss drug from Novo Nordisk, will be available through several leading telehealth providers, ...